Jim Cramer's top 10 things to watch in the stock market Monday

Market sentiment is buoyed by progress towards a U.S. government shutdown resolution. In M&A, Pfizer acquired obesity drug developer Metsera for $10 billion, intensifying competition in the GLP-1 market, where Eli Lilly received a significant price target hike and upgrade from Leerink. Nvidia saw its price target raised by Citi, despite Taiwan Semi reporting slower sales growth and broader concerns about AI boom sustainability. Meanwhile, JPMorgan issued a mixed outlook for major retailers, cutting price targets for several amid a challenging consumer environment ahead of next week's earnings.

Analysis

The market is showing a mildly positive sentiment, with the S&P 500 tracking higher following significant progress towards a U.S. government shutdown resolution, which could avert federal layoffs. This macro development provides a foundational uplift, aligning with previous market expectations for a positive outcome.

In the technology sector, Nvidia (NVDA) saw its price target hiked to $220 from $210 by Citi, despite a recent 7% loss, as analysts anticipate strong quarterly sales and guidance. However, this optimism is tempered by Taiwan Semi (TSM) reporting its slowest monthly sales growth in 18 months and broader investor concerns regarding the sustainability of the artificial intelligence boom.

The pharmaceutical landscape is dynamic, with Pfizer (PFE) acquiring Metsera for $10 billion, signaling its aggressive entry into the lucrative GLP-1 market, currently dominated by Novo Nordisk (NVO) and Eli Lilly (LLY). Eli Lilly received a significant boost, with Leerink upgrading it to Buy and raising its price target to $1,104 from $886, citing expanded Medicare and Medicaid coverage for obesity treatments. Conversely, Bristol Myers (BMY) faced a price target cut to $64 from $66 by Piper Sandler.

JPMorgan issued a mixed outlook for consumer retail, lowering price targets for Target (TGT), Lowe's (LOW), and Home Depot (HD), while raising Walmart's (WMT), indicating a challenging environment for the sector ahead of upcoming earnings reports. Other notable analyst actions include a price target cut for Zimmer Biomet (ZBH) following a weak earnings report and for DraftKings (DKNG) despite its recent partnerships.

Key Decisions for Investors

• Monitor the finalization of the U.S. government shutdown resolution for sustained market stability and potential sector-specific impacts.
• Evaluate the long-term growth prospects and competitive landscape within the GLP-1 market, considering Pfizer's strategic entry and Eli Lilly's strong analyst sentiment and expanded coverage.
• Assess the sustainability of AI-driven growth, balancing positive analyst outlooks for key players like Nvidia with broader concerns highlighted by Taiwan Semi's sales slowdown.
• Exercise caution in consumer-related retail stocks given the 'tough environment' noted by JPMorgan, pending next week's earnings reports for further clarity on sector performance.